WO2000042990A1 - Liposome formulations - Google Patents
Liposome formulations Download PDFInfo
- Publication number
- WO2000042990A1 WO2000042990A1 PCT/US2000/001743 US0001743W WO0042990A1 WO 2000042990 A1 WO2000042990 A1 WO 2000042990A1 US 0001743 W US0001743 W US 0001743W WO 0042990 A1 WO0042990 A1 WO 0042990A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- pest
- ivermectin
- lipid
- lipid phase
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 237
- 238000009472 formulation Methods 0.000 title claims abstract description 152
- 239000002502 liposome Substances 0.000 title claims abstract description 110
- 241000607479 Yersinia pestis Species 0.000 claims abstract description 131
- 239000003630 growth substance Substances 0.000 claims abstract description 51
- 239000000575 pesticide Substances 0.000 claims abstract description 49
- 206010061217 Infestation Diseases 0.000 claims abstract description 23
- 239000013543 active substance Substances 0.000 claims description 118
- 150000002632 lipids Chemical class 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 87
- 239000012071 phase Substances 0.000 claims description 72
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 67
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 65
- 229960002418 ivermectin Drugs 0.000 claims description 65
- 239000008346 aqueous phase Substances 0.000 claims description 54
- 150000003904 phospholipids Chemical class 0.000 claims description 36
- 241001465754 Metazoa Species 0.000 claims description 34
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000007864 aqueous solution Substances 0.000 claims description 30
- 239000003963 antioxidant agent Substances 0.000 claims description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 230000003078 antioxidant effect Effects 0.000 claims description 27
- 239000003937 drug carrier Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241001674048 Phthiraptera Species 0.000 claims description 17
- -1 indalone Chemical compound 0.000 claims description 15
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 239000000642 acaricide Substances 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 239000002917 insecticide Substances 0.000 claims description 10
- 241000255925 Diptera Species 0.000 claims description 9
- NIQCNGHVCWTJSM-UHFFFAOYSA-N Dimethyl phthalate Chemical compound COC(=O)C1=CC=CC=C1C(=O)OC NIQCNGHVCWTJSM-UHFFFAOYSA-N 0.000 claims description 8
- 230000000507 anthelmentic effect Effects 0.000 claims description 8
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 8
- 208000028454 lice infestation Diseases 0.000 claims description 8
- 241000238421 Arthropoda Species 0.000 claims description 7
- 239000005927 Pyriproxyfen Substances 0.000 claims description 7
- 229960002903 benzyl benzoate Drugs 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 150000002334 glycols Chemical group 0.000 claims description 7
- 201000002266 mite infestation Diseases 0.000 claims description 7
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 claims description 7
- 230000001846 repelling effect Effects 0.000 claims description 7
- 241000238876 Acari Species 0.000 claims description 6
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 claims description 6
- 230000000895 acaricidal effect Effects 0.000 claims description 6
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 6
- 229960001950 benzethonium chloride Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229930003799 tocopherol Natural products 0.000 claims description 6
- 235000010384 tocopherol Nutrition 0.000 claims description 6
- 239000011732 tocopherol Substances 0.000 claims description 6
- 229960001295 tocopherol Drugs 0.000 claims description 6
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 229940124339 anthelmintic agent Drugs 0.000 claims description 5
- 239000000921 anthelmintic agent Substances 0.000 claims description 5
- 239000013057 ectoparasiticide Substances 0.000 claims description 5
- 230000000590 parasiticidal effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 claims description 4
- 206010063409 Acarodermatitis Diseases 0.000 claims description 4
- 244000166675 Cymbopogon nardus Species 0.000 claims description 4
- 235000018791 Cymbopogon nardus Nutrition 0.000 claims description 4
- 239000005891 Cyromazine Substances 0.000 claims description 4
- 239000005912 Lufenuron Substances 0.000 claims description 4
- 241000447727 Scabies Species 0.000 claims description 4
- 235000001671 coumarin Nutrition 0.000 claims description 4
- 229960000956 coumarin Drugs 0.000 claims description 4
- LVQDKIWDGQRHTE-UHFFFAOYSA-N cyromazine Chemical compound NC1=NC(N)=NC(NC2CC2)=N1 LVQDKIWDGQRHTE-UHFFFAOYSA-N 0.000 claims description 4
- 229950000775 cyromazine Drugs 0.000 claims description 4
- 229960001673 diethyltoluamide Drugs 0.000 claims description 4
- FBSAITBEAPNWJG-UHFFFAOYSA-N dimethyl phthalate Natural products CC(=O)OC1=CC=CC=C1OC(C)=O FBSAITBEAPNWJG-UHFFFAOYSA-N 0.000 claims description 4
- 229960004118 dimethylcarbate Drugs 0.000 claims description 4
- VGQLNJWOULYVFV-SPJNRGJMSA-N dimethylcarbate Chemical compound C1[C@H]2C=C[C@@H]1[C@H](C(=O)OC)[C@@H]2C(=O)OC VGQLNJWOULYVFV-SPJNRGJMSA-N 0.000 claims description 4
- 229960001826 dimethylphthalate Drugs 0.000 claims description 4
- 229960005082 etohexadiol Drugs 0.000 claims description 4
- AVIYEYCFMVPYST-UHFFFAOYSA-N hexane-1,3-diol Chemical compound CCCC(O)CCO AVIYEYCFMVPYST-UHFFFAOYSA-N 0.000 claims description 4
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 claims description 4
- 229960000521 lufenuron Drugs 0.000 claims description 4
- 229930002897 methoprene Natural products 0.000 claims description 4
- 229950003442 methoprene Drugs 0.000 claims description 4
- 239000002297 parasiticide Substances 0.000 claims description 4
- 208000005687 scabies Diseases 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- ZCVAOQKBXKSDMS-AQYZNVCMSA-N (+)-trans-allethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(CC=C)C(=O)C1 ZCVAOQKBXKSDMS-AQYZNVCMSA-N 0.000 claims description 3
- FMTFEIJHMMQUJI-NJAFHUGGSA-N 102130-98-3 Natural products CC=CCC1=C(C)[C@H](CC1=O)OC(=O)[C@@H]1[C@@H](C=C(C)C)C1(C)C FMTFEIJHMMQUJI-NJAFHUGGSA-N 0.000 claims description 3
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims description 3
- 241000258242 Siphonaptera Species 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 240000004460 Tanacetum coccineum Species 0.000 claims description 3
- 241000331598 Trombiculidae Species 0.000 claims description 3
- 241000607598 Vibrio Species 0.000 claims description 3
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 claims description 3
- 229940024113 allethrin Drugs 0.000 claims description 3
- 229960002643 clofenotane Drugs 0.000 claims description 3
- 229960003338 crotamiton Drugs 0.000 claims description 3
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 3
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 claims description 3
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008350 hydrogenated phosphatidyl choline Substances 0.000 claims description 3
- 229960002809 lindane Drugs 0.000 claims description 3
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 3
- 229940015367 pyrethrum Drugs 0.000 claims description 3
- 229940080817 rotenone Drugs 0.000 claims description 3
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- 125000002640 tocopherol group Chemical group 0.000 claims description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 26
- 230000003071 parasitic effect Effects 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 18
- 241000282326 Felis catus Species 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 241000790252 Otodectes cynotis Species 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 235000006708 antioxidants Nutrition 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 210000005069 ears Anatomy 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 8
- 229940042585 tocopherol acetate Drugs 0.000 description 8
- 235000010469 Glycine max Nutrition 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 241000517307 Pediculus humanus Species 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 241000517304 Pthirus pubis Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 230000000366 juvenile effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000002691 unilamellar liposome Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000243985 Onchocerca volvulus Species 0.000 description 2
- 241000517306 Pediculus humanus corporis Species 0.000 description 2
- 241000509427 Sarcoptes scabiei Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960003872 benzethonium Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 230000000361 pesticidal effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940117013 triethanolamine oleate Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000517324 Pediculidae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VQXSOUPNOZTNAI-UHFFFAOYSA-N Pyrethrin I Natural products CC(=CC1CC1C(=O)OC2CC(=O)C(=C2C)CC=C/C=C)C VQXSOUPNOZTNAI-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 230000000856 effect on pests Effects 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 244000000053 intestinal parasite Species 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229930014550 juvenile hormone Natural products 0.000 description 1
- 239000002949 juvenile hormone Substances 0.000 description 1
- 150000003633 juvenile hormone derivatives Chemical class 0.000 description 1
- 229930191400 juvenile hormones Natural products 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 208000003177 ocular onchocerciasis Diseases 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229960000490 permethrin Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 1
- VJFUPGQZSXIULQ-XIGJTORUSA-N pyrethrin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-XIGJTORUSA-N 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229940035673 stromectol Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
- A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Definitions
- the present invention relates to a formulation for the delivery of pest growth regulators, pest repeilants and pesticides using liposomes. More specifically, the invention relates to liposome formulations containing ivermectin.
- ivermectin belongs is described in Chabala, et al., U.S. Patent No. 4,199,569. These compounds have parasiticidal activity as anthelmintics, insecticides, ectoparasiticides and acaracides and have been found to be useful in the treatment of parasitic infestations affecting animals, including humans. More specifically, ivermectin is classified as a veterinary therapeutic for use as an anthelmintic, insecticide and acaricide, while the human therapeutic classification is as an anthelmintic, more specifically for the treatment of human onchocerciasis (river blindness).
- ivermectin a commercially available ivermectin formulation is Stromectol (Merck & Co.), which is available in a solid dosage form.
- a formulation using surface modified microcapsules that contain active agents such as ivermectin is described by Speaker, et al, U.S Patent No. 5,686,113.
- the following disclosures describe several other means for delivery of insect repeilants. Lau, et al., U.S. Patent No. 5,173,303 describes a liposome formulation for the delivery of the insecticide N, N diethyl-m-toluamide (DEET). Unger, et al., U.S. Patent No.
- Therapeutic agents are also shown to be administered in a liposome formulation having a relatively high (20-40 wt%) alcohol content (Touitou, U.S. Patent No. 5,716,638).
- Wallach, et al., U.S. Patent No. 5,019,392 describes one formulation that minimizes the use of organic solvents by use of non-phospholipid vesicles.
- Liposomes are vesicles made of membrane-like lipid bilayers separated by aqueous layers. Liposomes have been widely used to encapsulate biologically active agents for use as drug carriers since water- or lipid-soluble substances may be entrapped within the aqueous layers or within the bilayers themselves. There are numerous variables that can be adjusted to optimize this drug delivery system. These include, the number of lipid layers, size, surface charge, lipid composition and the methods of preparation.
- liposomes Most pharmaceutical applications of liposomes have focused on their use in injectable formulations. However, use of liposomes in topical formulations has been shown to provide for better drug delivery than conventional vehicles, both from the standpoint of enhanced penetration and enhanced localization. See for example,
- the present invention provides for an improved means and method for delivery of pest growth regulators, pest repeilants and pesticides using a liposome-based formulation.
- the present invention relates to a liposome composition
- a liposome composition comprising 0.001 to 10.0 wt% of at least one active agent selected from the group consisting of pest growth regulators, pest repeilants and pesticides, where the composition comprises about 2.0 to 18.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- the present invention also relates to a composition comprising lipid vesicles having ivermectin encapsulated therein in an amount of between about 0.001 to 10.0 wt% of the composition.
- the invention in a second aspect, relates to a liposomal pharmaceutical composition
- a liposomal pharmaceutical composition comprising: (a) a lipid phase comprising phospholipids and at least one active agent; and (b) an aqueous phase comprising an aqueous solution; the active agents being selected from the group consisting of pest growth regulators, pest repeilants and pesticides.
- the aqueous phase may further comprise one or more excipients and one or more active agents.
- the lipid phase may further comprise a pharmaceutical carrier, an antioxidant and modifying agents.
- Still another aspect of the invention pertains to a method for treating a pest infestation which comprises administering a therapeutically effective amount of a pesticide encapsulated within lipid vesicles in a liposome formulation which comprises about 2.0 to 18.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- the pesticide typically comprises 0.005 to 50.0 wt% of the lipid phase.
- the invention in another aspect, relates to a method for controlling a pest population which comprises administering a therapeutically effective amount of a pest growth regulator encapsulated within lipid vesicles in a liposome formulation about 2.0 tol8.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- the pest growth regulator typically comprises 0.005 to 50.0 wt% of the lipid phase.
- Another aspect of the invention pertains to a method for repelling pests which comprises administering a therapeutically effective amount of a pest repellant encapsulated within lipid vesicles in a liposome formulation about 2.0 tol ⁇ .O wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- the pest repellant typically comprises 0.005 to 50.0 wt% of the lipid phase.
- the invention pertains to a method for treating parasitic infestations, which comprises administering a composition comprising lipid vesicles having ivermectin encapsulated therein in an amount of between about 0.001 to 10.0 wt% of said composition.
- the parasitic infestation is a lice infestation and administration is by topical application to the skin or hair.
- the parasitic infestation is a mite infestation and administration is by topical application to the ears.
- Another aspect of the invention relates to a method of treating a lice or mite infestation on an animal by topically administering ivermectin, which comprises the step of topically applying an ivermectin-containing liposome formulation to the skin or hair of an animal, said application being about 0.005 to 0.5 grams of formulation per square centimeter of skin.
- the invention also pertains to an article of manufacture comprising a container in association with instructions and/or a label indicating that the subject composition can be used to control pests, i.e., used as a pest growth regulator, pest repellant or pesticide and holding a composition comprising lipid vesicles having at least one pest growth regulator, pest repellant or pesticide encapsulated therein, where the composition comprises about 2.0 tol 8.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- compositions based on liposomes are particularly suitable for use with pest growth regulators, pest repeilants and pesticides.
- the benefits of liposomes are believed to be related to favorable changes in tissue distribution and pharmacokinetic parameters that result from liposome entrapment of active agents, and may be applied to pest growth regulators, pest repeilants and pesticides.
- the formulations of the instant invention provide for improved active agent delivery such that a minimal amount of active agent is needed to obtain the desired effect. Controlled release liposome liquid pharmaceutical formulations for injection, oral or rectal administration can also be used.
- liposomes in the methods and formulations described herein will have broad utility in the improved delivery of pest growth regulators, pest repeilants and pesticides to an animal or agricultural plants.
- Animals to be treated include humans, companion animals (e.g., feline and canine), and agriculturally bred animals such as horses and including those raised for human consumption, such as bovine, porcine and poultry (e.g. avian).
- active agent is intended to mean any compound or composition that, when present in a therapeutically effective amount, produces an effect on pests, more specifically a negative effect such as one that eradicates pests, or hinders growth and development, or acts as a deterrent, and so forth. More specifically, the term active agent is used to collectively refer to pest growth regulators, pest repeilants and pesticides. The term “active agent” is also intended to include use of a single active agent or use of several active agents in combination.
- At least one active agent will be encapsulated within the liposomes, while any additional active agents may be encapsulated in the same liposomes as the first active agent, may be encapsulated within separate liposomes or may be included within the aqueous phase.
- arthropod growth regulators is used to mean an active agent used to regulate pest growth, and insect growth in particular, or to prevent re- infestation by attacking the newly hatched or juvenile stage pests.
- arthropod growth regulators include, by way of illustration and not limitation, agents such as methoprene, pyriproxyfen, lufenuron and cyromazine.
- Pest repeilants is used to mean an active agent that repels or deters pests from animals or agricultural plants which have been treated with the agent and includes, by way of illustration and not limitation, agents such as citronella, dimethyl phthalate, dimethyl carbate, ethohexadiol, diethyltoluamide, indalone, benzyl benzoate, 2-ethyl-l,3-hexanediol and coumarin. Pest repeilants also include agents that prevent pests from being attracted to a treated animal or plant, for example by masking, altering or neutralizing any scent or chemical on the animal or plant that attracts pests.
- the term "pesticides” is used to mean an active agent used to attack and eradicate those pests or parasites that are know to infest and/or harm animals or agricultural plants, in particular those that infest the skin and/or hair of an animal.
- the term “pesticide” includes, by way of illustration and not limitation, parasiticides, ectoparasiticides, acaricides, miticides and anthelmintics, along with specific agents such as ivermectin, benzyl benzoate, chlorophenothane, crotamiton, lindane, precipitated sulfur, pyrethrum, rotenone and allethrin.
- Pesticides such as ivermectin are particularly suited for combination with a pest growth regulator and/or pest repellant, such that one an infestation of adult pests has been eradicated, re- infestation is prevented either by hindering egg or juvenile stage development or by repelling adult pests.
- pest refers to organisms and microorganisms, including pathogens, that negatively affect animals and plants by colonizing, attacking or infecting them, and includes those organisms that spread disease and/or damage the animal and/or compete for host nutrients.
- pest organisms include, by way of illustration, and not limitation arthropods, bacteria, and parasitic worms such as nematodes.
- Arthropods include insects such as fleas, mosquitoes, lice (including those that infest humans such as Pediculus humanus capitis, head louse, Pediculus humanus corporis, body or clothes louse, and Phthirus pubis, crab louse), biting gnats, flies, scabies (more accurately, Sarcoptes scabiei, the parasite that causes scabies) and vibrio vulnifwa; and arachnids such as spiders, ticks and mites such as chiggers.
- the term "pest” is intended to include those pests of agricultural plants such as plant mites, aphids and locusts.
- a liposome formulation is used for the topical application of ivermectin to treat diseases caused by lice, scabies and mites and for the oral administration to treat diseases caused by parasites such as those belonging to the Ascaridae family, in particular Ascaridae Galli and Ascaridae canus, which attack the fatty tissues of chickens, pigs, dogs and cats.
- Ivermectin can be used in combination with a pest growth regulator such as pyriproxyfen, which may be encapsulated with the ivermectin, encapsulated in separate liposomes which are then mixed with the ivermectin-containing liposomes, or added to the aqueous phase.
- a pest growth regulator such as pyriproxyfen
- lipids or lipophilic substances are dissolved in an organic solvent.
- the solvent is removed, such as under vacuum by rotary evaporation, the lipid residue forms a film on the wall of the container.
- An aqueous solution that typically contains electrolytes or hydrophilic biologically active materials are then added to the film.
- Large MLNs are produced upon agitation.
- the larger vesicles are subjected to sonication or sequential filtration through filters with decreasing pore size.
- pressurized extrusion Barenholz, et al., FEBS Lett. 99:210-214 (1979)).
- Liposomes can also take the form of unilamellar vesicles, which are prepared by more extensive sonication of MLVs, and consist of a single spherical lipid bilayer surrounding an aqueous solution.
- Unilamellar vesicles can be small, having diameters within the range of 200-500 A, while larger ULNs can have diameters within the range of 1000-10,000 A.
- UPNs Unilamellar vesicles
- Small ULNs can also be prepared by the ethanol injection technique described by Batzri, et al., Biochim et Biophys Acta 298:1015-1019 (1973) and the ether injection technique of Deamer, et al. Biochim et Biophys Acta 443:629-634 (1976). These methods involves the rapid injection of an organic solution of lipids into a buffer solution, which results in the rapid formation of unilamellar liposomes.
- Another technique for making ULNs is taught by Weder, et al. in "Liposome Technology", ed. G. Gregoriadis, CRC Press Inc., Boca Raton. Florida, Nol. I, Chapter 7, pg. 79-107 (1984).
- This detergent removal method involves solubilizing the lipids and additives with detergents by agitation or sonication to produce the desired vesicles.
- Papahadjopoulos, et al., U.S. Patent 4,235,871 describes the preparation of large ULNs by a reverse phase evaporation technique that involves the formation of a water-in-oil emulsion of lipids in an organic solvent and the material to be encapsulated in an aqueous buffer solution. The organic solvent is removed under pressure to yield a mixture which, upon agitation or dispersion in an aqueous media , is converted to large ULNs.
- Suzuki et al., U.S. Patent No. 4,016,100 describes another method of encapsulating agents in unilamellar vesicles by freezing an aqueous phospholipid dispersion of the agent and lipids.
- liposomes can also be multivesicular.
- these multivesicular liposomes are spherical and contain internal granular structures.
- the outer membrane is a lipid bilayer and the internal region contains small compartments separated by bilayer septrum.
- a comprehensive review of all the aforementioned lipid vesicles and methods for their preparation are described in "Liposome Technology", ed. G. Gregoriadis, CRC Press Inc., Boca Raton, Florida, Nol. I, II, & III (1984).
- Mezei, et al., U.S. Patents No. 4,485,054 and Mezei, U.S. Patents No. 4,761,288 also describe methods of preparing lipid vesicles.
- one or more active agents are dissolved or dispersed in a lipid- containing organic solvent.
- the solvent is then evaporated, usually under reduced pressure, to yield a thin lipid film containing the active agent(s).
- the lipid film is then hydrated, with agitation, using a aqueous phase containing any desired electrolytes and lipid vesicles containing the active agent(s) are produced.
- the invention also contemplates the inclusion of additional materials in the formulations to facilitate active agent delivery, formulation stability, and so forth.
- additional materials such as conventional thickeners and gelling agents can also be added to provide a formulation having the desired consistency for topical application.
- a modifying agent such as a preservative, an antioxidant or excipients will often be added to the formulation.
- the amount of active agent to be included in the liposome formulation can vary within wide limits depending upon the intended application and the lipid used. Further, while one active agent will be encapsulated within the liposomes, any additional active agents may be encapsulated within the same or different liposomes or may be added to the aqueous phase.
- the level of the active agent in the liposome formulation of the invention can vary within the full range employed by those skilled in the art, e.g., from about 0.001 weight percent (wt%) to about 99.99 wt% of the active agent based on the total formulation, with the balance (about 0.01-99.99 wt%) being the lipid and aqueous phase substituents. However, the formulations of the invention contemplate some preferred ranges of active agent, which are set forth in detail below.
- the active agent is administered at a therapeutically effective amount, e.g., a dosage sufficient to provide treatment for the disease state being treated, for example a parasitic infestation.
- Administration of the active agent- liposome formulation can be via any of the accepted modes of administration for agents that serve similar utilities.
- This invention is intended to be utilized for any disease state treated by the active agents in their current commercially available forms.
- one embodiment for the invention pertains to a method for treating a pest infestation which comprises administering a therapeutically effective amount of a pesticide encapsulated within lipid vesicles in a liposome formulation.
- a pest population can be controlled by administering a therapeutically effective amount of a pest growth regulator encapsulated within lipid vesicles in a liposome formulation, and pests can be repelled by administering a therapeutically effective amount of a pest repellant encapsulated within lipid vesicles in a liposome formulation.
- any of the aforementioned methods can also include one or more other active agents that function the same as or different from the first active agent, for example, a method for treating a pest infestation can involve administering a pesticide alone, or in combination with one or more other pesticides, pest growth regulators and/or pest repeilants.
- a liposome composition comprises 0.001 to 10.0 wt% of at least one active agent selected from the group consisting of pest growth regulators, pest repeilants and pesticides, where the composition comprises about 2.0 to 18.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- a liposomal pharmaceutical composition comprises: (a) a lipid phase comprising phospholipids and at least one active agent; and (b) an aqueous phase comprising an aqueous solution and optionally further comprising one or more active agents; the active agents being selected from the group consisting of pest growth regulators, pest repeilants and pesticides.
- a preferred active agent-liposome formulation or composition has a lipid and aqueous phase, and will contain active agents in an amount of about 0.001 to 10.0 wt% of the total formulation. However, more typically, the total amount of active agents will be about 0.001 to 0.5 wt% of the total formulation, with a preferred range being about 0.001 to 0.2 wt% of the total formulation.
- the formulations of the invention comprise about 2.0 to 18.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- An exemplary formulation is comprised of about 9.5 wt% lipid phase and about 90.5 wt% aqueous phase, and contains about 0.001 to 0.1 wt% of active agent(s).
- the lipid phase contains at least one active agent and phospholipids.
- the lipid phase may optionally contain one or more pharmaceutical carriers (as described above), an antioxidant and other modifying agents.
- the lipid phase contains about 0.005 to 50.0 wt% active agent, typically about 0.005 to 25.0 ⁇ vt% active agent, and preferably about 0.005 to 7.0 wt%. These ranges refer to the total amount of active agents present in the lipid phase.
- the lipid phase may comprise about 2.0 to 75.0 wt% phospholipids, typically about 25.0 to 45.0 wt% phospholipids.
- Numerous lipids are useful in the manufacture of the lipid phase of the formulation of the invention, and include by way of illustration and not limitation, phospholipids such as phosphatidyl chlolines, lysophosphatidyl chlolines, phosphatidyl serines, phosphatidyl ethanolamines, phosphatidyl inositols, cardiolipin, and sphingomyelin; natural phospholipids such as egg yolk lecithin, soybean lecithin, and soybean oil based phospholipids; glycolipids, dialkyl-type synthetic surfactants; polar lipids and neutral lipids; fatty acids; and the like.
- phospholipids and hydrogenated phospholipids are particularly useful.
- Soybean oil based phospholipids are well suited for use in the invention, for example the hydrogenated phosphatidylcholine, Phospholipon ® 90H ("PH-90H”) and the hydrogenated phosphatidylcholine, Phospholipon ® 80H (“PH-80H”), manufactured by American Lecithin Company, Oxford, Connecticut.
- PH-90H hydrogenated phosphatidylcholine
- Phospholipon ® 80H Phospholipon ® 80H
- the lipid phase may optionally contain one or more pharmaceutically acceptable carriers, comprising from about 0 to 70.0 wt% of the lipid phase, and typically from about 40.0 to 60.0 wt% of the lipid phase.
- pharmaceutically acceptable carriers are suitable for use in the invention, as are described herein, and may be used alone or in combination.
- Preferred carriers include glycols such as propylene glycol, polyethylene glycol, polypropylene glycol and glycol ethers, and low molecular weight alcohols (C ⁇ - 6 ) such as 200 proof ethanol, along with a combination of a glycol and low molecular weight alcohol. Such combinations are typically within the range of about 50 to 100 wt% alcohol and 0 to 50 wt% glycol.
- the lipid phase may optionally also contain about 0 to 20.0 wt% of an antioxidant, more typically about 1.0 to 15.0 wt% antioxidant.
- an antioxidant typically about 1.0 to 15.0 wt% antioxidant.
- suitable antioxidants are well known in the art.
- the preferred antioxidant is tocopherol or a tocopherol derivative, more preferably Vitamin E ( ⁇ -tocopherol acetate).
- ⁇ -Lipoic Opti-pure, Los Angeles, CA is also well suited for use as an antioxidant.
- the lipid phase may optionally contain one or more suitable modifying agents such as are well known in the art and include materials such as conventional thickeners, gelling agents, preservatives, stabilizers, emulsifiers, and so forth.
- suitable modifying agents include, by way of illustration and not limitation, stearylamine, phosphatidic acid, dicetyl phosphate, sterols, cholesterol and cholesterol stearate, lanolin extracts, hydroxypropylmethylcellulose, carboxymethylcellulose, sorbitol, and the like.
- the amount of modifying agents will range from about 0 to 12.0 wt% of the lipid phase, typically about 0.01 to 4.0 wt% of the lipid phase.
- the aqueous phase comprises an aqueous solution and may optionally comprise one or more excipients and/or active agents.
- the aqueous phase comprises about 0 to 2.0 wt% of one or more excipients, about 0 to 5.0 wt% of one or more active agents, with the balance of the aqueous phase comprising about 93.0 to 100.0 wt% aqueous solution.
- An exemplary aqueous phase is comprised of about 99.90 wt% aqueous solution and about 0.10 wt% excipients.
- the aqueous phase may optionally contain one or more active agents which, when present, will preferably comprise about 0.001 to 5.0 wt% of the aqueous phase.
- the aqueous solution is preferably sterile water such as distilled water, but use of other aqueous solutions are also contemplated by the invention. These include, by way of example, a physiological saline solution, a buffer solution such as an aqueous solution of NaCl and sodium bicarbonate, a CaCl 2 solution, an aqueous carbohydrate solution, detuerated water, or other isotopic forms of H 2 0, buffered solutions of organic acids and bases, and the like, or any combination thereof.
- Excipients when present, will preferably comprise about 0.10 to 2.0 wt%, preferably 0.10 to 0.20 wt% of the aqueous phase.
- Suitable excipients for inclusion in the aqueous phase include, for example, preservatives and detergents.
- Dowicil 2000TM brand l-(cis-3-chloroallyl)-3,5,7-triaza-l-azoniaadamantane chloride, manufactured by Dow Chemical has been found to be a particularly suitable preservative.
- Another suitable preservative which may in some formulations be preferable, is benzethonium chloride.
- Typical pharmaceutically acceptable detergents include Tween 80.
- the aqueous phase may also contain a water soluble organic solvent such as, by way of illustration and not limitation, polyhydric alcohols including glycerin, propylene glycol, polypropylene glycol, triethylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, etc.; alcohols such as benzyl alcohols, etc.; ethers; ketones; esters and glycerin esters such as monoacetin, diacetin, glycerophosphoric acid, etc.; and various aromatic and aliphatic hydrocarbons including fluorocarbons.
- a water soluble organic solvent such as, by way of illustration and not limitation, polyhydric alcohols including glycerin, propylene glycol, polypropylene glycol, triethylene glycol, polyethylene glycol, diethylene glycol monoethyl ether, etc.; alcohols such as benzyl alcohols, etc.; ethers; ketones; esters and glycerin esters such as mono
- a Preferred WT % A More Preferred WT % Of Lipid Of Aqueous Of Lipid Of Aqueous
- the formulations of the invention may also contain other ingredients such as are well know in the formulations art.
- the invention also encompasses a formulation wherein the lipid phase consists essentially of 0.005 to 50.0 wt% active agent, 10.0 to 70.0 wt% phospholipids, 0 to 70.0 wt% pharmaceutical carrier, 0 to 20.0 wt% antioxidant. and 0 to 12.0 wt% of one or more modifying agents; more preferably consisting essentially of 0.005 to 7.0 wt% active agent. 25.0 to 45.0 wt% phospholipids, 40.0 to 60.0 wt% pharmaceutical carrier, 1.0 to 15.0 wt% antioxidant, and 0.01 to 4.0 wt% modifying agent(s).
- the aqueous phase may consist essentially of 93.0 to 100.0 wt% aqueous solution, 0 to 2.0 wt% excipients and 0 to 5.0 wt% active agents; more preferably consisting essentially of 93.0 to 99.90 wt% aqueous solution and 0.10 to 0.20 wt% excipients.
- a particularly useful formulation for use in the methods of the invention is a composition comprising lipid vesicles having ivermectin encapsulated therein in an amount of between about 0.001 to 10.0 wt% of the total composition.
- Particularly preferred compositions are formed as suspensions and contain ivermectin as the active agent in an amount within the range of about 0.001 to 0.1 wt% of the total formulation.
- Such formulations preferably contain ivermectin as the active agent in an amount within the range of about 0.01 to 1.0 wt% of the lipid phase, with 0.1 to 1.0 wt% of the lipid phase being preferred.
- Ivermectin (pharmacopeial grade) is typically at least 80 wt% 22,23- dihydroavermectin B ⁇ a and not more than 20 wt% 22,23-dihydroavermectin Bi b , i-e., 80-100 wt% of the former and 0-20 wt% of the latter.
- Table II One preferred formulation is described in Table II, where the components of the formulations are described, both as a weight percent of their respective phase (lipid or aqueous) and as a weight percent of the total formulation. This formulation can be made by methods such as are well known in the art.
- Example 1 The method used to make the formulations used in Example 1 involved adding ivermectin (pharmacopeial grade), soy phosphatidylcholine (PH-90H and PH-80H), cholesterol (Sigma Chem. Co.) and Vitamin E acetate (Spectrum Chemical Co.) to ethanol.
- This lipid phase was heated at 55-65°C, and gently stirred until a clear solution resulted, and was maintained at the prescribed temperature.
- Benzethonium chloride (Spectrum Chemical Co.) was added to the sterile water (Baxter) and the resulting aqueous phase was heated to 50-65°C and maintained at the desired temperature.
- the lipid phase was then injected into the aqueous phase, while the aqueous phase was simultaneously being agitated.
- Table II Exemplary 0.1 wt% Tonical Liposome Formulation
- Aqueous solution Water (sterile) 99.9 90.35
- the active agent-liposome formulation for treatment of the above conditions is designed for topical or transdermal administration.
- an ivermectin-liposome formulation of the invention would be applied topically to the hair and scalp of the infested animal.
- the formulation also includes a pest growth regulator such as pyriproxyfen.
- a pest growth regulator such as pyriproxyfen.
- Another example is the topical application of ivermectin to the ears of an animal suffering from a mite infestation. It is understood however, that any pharmaceutically acceptable mode of administration can be used.
- administration can be via any accepted systemic or local route, for example, via parenteral, oral (particularly for infant formulations), intravenous, nasal, bronchial inhalation (i.e., aerosol formulation), and so forth.
- Rectal administration in the form of a suppository is particularly well suited for delivery of active agents that are directed against intestinal parasites.
- Oral administration to non-human animals is preferably by the addition of the active agent- liposome formulation to feed or drinking water.
- Administration to plants can be by spraying the formulation on the infested areas, for example.
- the active agent-liposome formulation can be in the form of solid, semi-solid or liquid or aerosol dosage forms, such as.
- composition of the invention may include additional conventional pharmaceutical carriers, excipients, other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.
- Carriers can be selected from the various oils, including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical carriers include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, glycols such as propylene glycol, polyethylene glycol, glycol ethers, polyglycols and similar compounds, water, low molecular weight alcohols (C ⁇ - 6 ) such as ethanol, cetyl alcohol, stearyl alcohol and other similar compounds, and the like.
- the formulation of the invention also preferably contains an antioxidant such as, by means of illustration and not limitation, tocopherol, more specifically Vitamin E ( ⁇ -tocopherol) and tocopherol derivatives, butylated hydroxyanisole, butylated hydroxytoluene, and so forth.
- an antioxidant such as, by means of illustration and not limitation, tocopherol, more specifically Vitamin E ( ⁇ -tocopherol) and tocopherol derivatives, butylated hydroxyanisole, butylated hydroxytoluene, and so forth.
- suitable pharmaceutical carriers and their formulations are described in "Remington's Pharmaceutical Sciences” by E. W. Martin.
- the liposome formulation to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
- non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.
- oral administration can be used to deliver the active agent- liposome formulation using a convenient daily dosage regimen which can be adjusted according to the degree of affliction.
- a pharmaceutically acceptable, non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, povidone, magnesium stearate, sodium saccharine, talcum, cellulose, croscarmellose sodium, glucose, gelatin, sucrose, magnesium carbonate, and the like.
- Such compositions take the form of solutions, suspensions, dispersible tablets, pills, capsules, powders, sustained release formulations and the like.
- the liposome formulations may take the form of a capsule, liquid suspension, pill or tablet and thus the formulation will contain, along with the active agent, a diluent such as lactose, sucrose, dicalcium phosphate, water, and the like; a disintegrant such as croscarmellose sodium, starch or derivatives thereof; a lubricant such as magnesium stearate and the like; and a binder such as a starch, polyvinylpyrrolidone, gum acacia, gelatin, cellulose and derivatives thereof, and the like, and may or may not contain a preservative such as benzethonium chloride and the like.
- a diluent such as lactose, sucrose, dicalcium phosphate, water, and the like
- a disintegrant such as croscarmellose sodium, starch or derivatives thereof
- a lubricant such as magnesium stearate and the like
- a binder such as a starch
- Liquid pharmaceutically administrable liposome formulations can, for example, be prepared by dissolving, dispersing, etc. the active agent (for example, about 0.5 to 20.0 wt%) and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension.
- a carrier such as, for example, water, saline, aqueous dextrose, glycerol, glycols, ethanol, and the like, to thereby form a solution or suspension.
- the liposome formulation to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting agents, suspending agents, emulsifying agents, or solubilizing agents or solubility enhancers, pH buffering agents and the like, for example, sodium acetate, sodium citrate, cyclodextrins and cyclodextrine derivatives, polyoxyethylene, sorbitan monolaurate or stearate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art.
- the formulation to be administered will, in any event, contain a quantity of the active agent in an amount effective to alleviate the symptoms of the subject being treated.
- a liquid formulation such as a syrup or suspension
- a liquid formulation such as a syrup or suspension
- the solution or suspension in for example propylene carbonate, vegetable oils or triglycerides, is preferably encapsulated in a gelatin capsule.
- the solution e.g. in a polyethylene glycol
- a pharmaceutically acceptable liquid carrier e.g. water
- liquid or semi-solid oral formulations may be prepared by dissolving or dispersing the active agent(s) in vegetable oils, glycols, triglycerides, propylene glycol esters (e.g. propylene carbonate) and the like, and encapsulating these solutions or suspensions in hard or soft gelatin capsule shells.
- Parenteral administration of the liposome formulations of the invention is generally characterized by injection, either subcutaneously, intramuscularly or intravenously, and can include intradermal or intraperitoneal injections as well as intrasternal injection or infusion techniques.
- Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like.
- the liposome formulations to be administered may also contain minor amounts of non-toxic auxiliary substances as described herein.
- the active agent can be administered parenterally, for example, by incorporating the active agent in a liposome formulation followed by dispersal into an acceptable infusion fluid.
- a typical daily dose of the active agent can be administered by one infusion, or by a series of infusions spaced over periodic intervals.
- suitable aqueous solutions of an active agent in water-soluble form for example in the form of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers.
- the active agent can also be in the form of a lyophilisate and can be made into a solution prior to parenteral administration by the addition of suitable solvents.
- the composition will comprise 0.02-8.0 wt% of the active agent in solution.
- a more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of dosage is maintained. See, e.g., U.S. Patent No. 3,710,795, which is hereby incorporated by reference.
- Aerosol administration is an effective means for delivering a liposome formulation directly to the respiratory tract and has the following advantages: it circumvents the effects of enzymatic degradation, poor absorption from the gastrointestinal tract, or loss of the active agent due to the hepatic first-pass effect; it administers active agents which would otherwise fail to reach their target sites in the respiratory tract due to their molecular size, charge or affinity to extra-pulmonary sites; it provides for fast absorption into the body via the alveoli of the lungs; and it avoids exposing other organ systems to the active agent, which is important where exposure might cause undesirable side effects.
- Nebulizer devices produce a stream of air that causes the active agent-liposome formulation to suspend as a mist which is carried into the patient's respiratory tract by inhalation.
- Metered-dose inhalers typically have the active agent-liposome formulation packaged with a compressed gas and, upon actuation, discharge a measured amount of the active agent by compressed gas, thus affording a reliable method of administering a set amount of active agent(s).
- Dry powder inhalers administer the active agent in the form of a free flowing powder that can be dispersed in the patient's air-stream during breathing by the device.
- the active agent is formulated with an excipient, such as lactose.
- an excipient such as lactose.
- a measured amount of the active agent is stored in a capsule form and is dispensed to the patient with each actuation. All of the above methods can be used for administering the present invention.
- binders and carriers include, for example, polyethylene glycols or triglycerides, for example PEG 1000 (96%) and PEG 4000 (4%).
- PEG 1000 polyethylene glycols or triglycerides
- PEG 4000 4%
- Such suppositories may be formed from mixtures containing the active agent in the range of from about 0.5-10 wt%; preferably from about 1-2 wt%.
- the liposome formulation of the invention can also be administered transdermally, which term is used to mean delivery of therapeutic agents through body surfaces and membranes, including by means of illustration and not limitation, buccal and mucosal membranes, body tissues, and skin (epithelium and stratum corneum), and will preferably include an effective amount of a permeation enhancer.
- Transdermal delivery can be accomplished by numerous means, for example, by topical application of a formulation such as a lotion, or by means of a transdermal or electrotransport active agent delivery system.
- a preferred method of administration of the liposomal formulation of the invention is topically, and without any permeation of the active agent into or through the skin (e.g., scalp, ears, etc) or other body surface (e.g., mucosal, buccal, etc.), i.e., the active agent is effective on the skin or other body surface.
- the active agent is effective on the skin or other body surface.
- a method of topically administering an active agent in the formulation of the invention involves the step of applying an active agent-containing liposome formulation to the skin or hair of an animal, said application being about 0.005 to 0.5 grams of liposome formulation per square centimeter of surface should be sufficient, with an amount of between 0.01 to 0.05 g/cm 2 being useful in many cases.
- the liposome formulations of the present invention may also be applied topically under occlusion to obtain enhanced effect.
- the compositions described herein have a wide variety of utilities in dealing with pests and the problems associated therewith.
- One embodiment of the invention pertains to a method for treating a pest infestation which comprises administering a therapeutically effective amount of a pesticide encapsulated within lipid vesicles in a liposome formulation which comprises about 2.0 to 18.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- the formulation can be administered by applying the formulation in the vicinity of the pest infestations such as a topical application on infected skin, for example, on the scalp or within the ears.
- the formulation can also be administered orally or rectally in an appropriate dosage form to treat internal pest infestations.
- This invention is also intended to be utilized to deliver a pesticide for the treatment of insect infestations such as vibrio vulnifica.
- a similar formulation having a pest growth regulator encapsulated within lipid vesicles can be used in a method for controlling a pest population.
- a similar formulation having a pest repellant encapsulated within lipid vesicles can be used in a method for repelling pests. This method finds particular utility in repelling pests such as chiggers, fleas, mosquitoes, biting gnats and flies, by delivering a suitable pest repellant.
- parasitic infestations are treated by administering a therapeutically effective amount of ivermectin encapsulated within lipid vesicles in a liposome formulation.
- the ivermectin is present therein in an amount of between about 0.001 to 10.0 wt% of said composition.
- this invention is intended to be utilized to deliver ivermectin for the treatment of diseases such as parasitic infestations, for example, lice, including those that infest humans such as Pediculus humanus capitis, Pediculus humanus corporis and Phthirus pubis (crab louse); mites; and Sarcoptes scabiei.
- ivermectin is particularly useful in the treatment of lice infestations as ivermectin is believed to kill not only the adult lice, but also to affect the viability of the eggs.
- the formulation may also include a pest growth regulator such as pyriproxyfen which specifically targets the juvenile stage.
- the infestation can be eradicated in one application of the ivermectin- liposome formulation of the invention.
- Current therapies are only effective at killing the adult lice, thus requiring subsequent treatments to kill each hatched generation.
- the term "therapeutically effective amount” refers to that amount of the active agent which, when administered to an animal in need thereof, is sufficient to effect treatment (as defined above) as a pest growth regulator, pest repellant or insecticide such as an anthelmintic, insecticide or acaricide.
- the amount that constitutes a “therapeutically effective amount” will vary depending on the condition or disease and its severity, and the animal to be treated, its weight, age, etc., but may be determined routinely by one of ordinary skill in the art with regard to contemporary knowledge and to this disclosure.
- treatment covers any treatment of a disease in an animal, particularly a human, and includes: (i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the disease, i.e. arresting its development; or (iii) relieving the disease, i.e. causing regression of the disease.
- the term "therapeutically effective amount” includes an effective pest growth regulating amount, an effective pesticidal amount and an effective pest-repelling amount, depending upon the particular application for which the formulation is being used.
- the efficacy of the formulation will be determined by the effect upon the pests, for example mortality, and the avoidance of adverse effects upon the animal being treated.
- an effective pest growth regulating amount is an amount of the liposome formulation, more specifically the active agent, where 90% or greater pest-growth regulation is achieved.
- an effective pesticidal amount is an amount of the liposome formulation, more specifically the active agent, where 90% or greater mortality against pests is achieved.
- An effective pest-repelling amount is an amount of the liposome formulation, more specifically the active agent, where 90% or greater of the pests are repelled from the animal being treated.
- the amount of liposome formulation or active agent used in the methods of the invention meets the growth regulation, mortality, or repelling criteria above, and preferably exhibits no adverse effects on the animal being treated.
- a daily dose is from about 0.01-100.0 mg/kg of body weight, preferably about 0.1-64.3 mg/kg of body weight, more typically about 0.3-43.0 mg/kg of body weight.
- the dosage range would be about 0.7 mg to 7 g per day, preferably about 7.0 mg to 4.5 g per day, and most preferably about 21 mg to 3.0 g per day.
- the amount of the active agent administered will, of course, be dependent on the subject and disease state being treated, the severity of the affliction, the manner and schedule of administration and the judgment of the prescribing physician. Such use optimization is well within the knowledge of those of ordinary skill in the art.
- An example of a suitable dosage is exemplified by a method of topically administering ivermectin comprising the step of applying an ivermectin-containing liposome formulation to the skin or hair of an animal, where the application is about 0.005 to 0.5 grams of formulation per square centimeter of skin, preferably about 0.01 to 0.05 grams of formulation per square centimeter of skin.
- Another embodiment of the invention pertains to an article of manufacture comprising a container in association with instructions and/or a label indicating that the subject composition can be used to control pests, i.e., used as a pest growth regulator, pest repellant or pesticide and holding a composition comprising lipid vesicles having at least one pest growth regulator, pest repellant or pesticide encapsulated therein, where the composition comprises about 2.0 to 18.0 wt% lipid phase and about 82.0 to 98.0 wt% aqueous phase.
- the instructions and/or label would provide information about methods of administering the composition, the dosage form, any contraindications, information regarding proper storage of the article, and so forth.
- the pest growth regulator, pest repellant or pesticide is present in an amount of between about 0.001 to 10.0 wt% of the composition.
- the pesticide is ivermectin.
- the composition may contain one or more additional active agents.
- Vitamin E acetate 1.099 1.09 1.0
- the dose of 0.01 % was chosen as the effective dose for the Target Animal Safety Study and the Clinical Field Trial. This decision was based on several factors, which are outlined as follows: Safety is not an issue because the dose of ivermectin delivered to the cat with the use of the liposome suspension (assuming 100 % absorption) was 100 ⁇ g.
- test substance (0.01 wt% ivermectin-liposome formulation) did not produce any adverse effects when administered to the ears of four week old kittens for three consecutive days at a dose rate of up to 5X the normal treatment level.
- the ear swabs were evaluated for the presence or absence of ear mites.
- Treatment with 0.5 ml of 0.01 wt% ivermectin-liposome formulation was administered if ear mites were found to be present.
- an examination of the ears was performed for clinical signs of ear mite infestation and ear swabs were evaluated for the presence or absence of ear mites.
- Example 2 The following trials were conducted to establish the dosage, efficacy and safety of ivermectin in a liposome suspension as a treatment for adult body lice (Pediculus humanus) in humans.
- Vitamin E acetate 1.10 1.099 1.09 1.0
- the lice were then placed in a test container, which was dipped into the insecticide formulation being evaluated (NIX ® and RID ® products, Control, 0.001 wt%, 0.01 wt% or 0.1 wt% ivermectin liposome formulation).
- the lice were kept under the pesticide for 1, 4 or 10 minutes, after which the container was placed in distilled water and agitated. The container was removed and the lice rinsed in water. The lice were transferred to an incubator, and mortality is evaluated at one hour and at 24 hours after treatment.
- Table VII Corrected Mean Percent Mortality
- NIX and the 0.1 wt% ivermectin liposome formulation provided 100% mortality 24 hours after immersion and water rinsing.
- the RID ® product while statistically inferior to the NIX ® product and the 0.1 wt% formulation, still provided a satisfactory 94.7% mortality.
- the 0.01 wt% ivermectin liposome formulation also provided 100% mortality 24 hours after immersion when the formulation was allowed to remain on the adult lice, without washing or rinsing. This formulation was less effective (only 38.1% mortality at +24 hours) when it was washed and rinsed off the lice.
- the 0.01 wt% ivermectin liposome formulation was the least effective as it provided only 17.5% mortality, even in the absence of a wash and rinse.
- Example 3 This example illustrates the preparation of a representative liposome formulation for administration of an active agent of the invention.
- the active agent, soy phosphatidylcholine and tocopherol acetate were dissolved in a chloroform:methanol (2: 1 v/v) solvent solution in a pear-shaped flask containing 100 g of small glass beads.
- the solvent was evaporated in a rotary evaporator at 30°C under reduced pressure until a thin, smooth film of the lipid and ivermectin was obtained on the surface of the glass beads and the wall of the flask.
- the resulting lipid film was hydrated at 55°C using the aqueous sodium chloride and sodium bicarbonate solution in an environment shaker for 30 minutes.
- the hydroxypropylmethylcellulose was added to the formulation within 5 seconds after the lipid film and aqueous solution were mixed.
- Example 4 This example illustrates the preparation of a representative liposome formulation for administration of an active agent of the invention.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU26272/00A AU781703B2 (en) | 1999-01-25 | 2000-01-24 | Liposome formulations |
JP2000594447A JP2002535268A (en) | 1999-01-25 | 2000-01-24 | Liposome formulation |
IL14456100A IL144561A0 (en) | 1999-01-25 | 2000-01-24 | Liposome compositions and methods for treating pests utilizing the same |
MXPA01007486A MXPA01007486A (en) | 1999-01-25 | 2000-01-24 | Liposome formulations. |
EP00904531A EP1154755A4 (en) | 1999-01-25 | 2000-01-24 | Liposome formulations |
IL144561A IL144561A (en) | 1999-01-25 | 2001-07-25 | Liposome compositions and methods for combating pests utilizing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11709499P | 1999-01-25 | 1999-01-25 | |
US60/117,094 | 1999-01-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000042990A1 true WO2000042990A1 (en) | 2000-07-27 |
Family
ID=22370960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/001743 WO2000042990A1 (en) | 1999-01-25 | 2000-01-24 | Liposome formulations |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1154755A4 (en) |
JP (1) | JP2002535268A (en) |
AU (1) | AU781703B2 (en) |
IL (2) | IL144561A0 (en) |
MX (1) | MXPA01007486A (en) |
WO (1) | WO2000042990A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001089500A2 (en) * | 2000-05-24 | 2001-11-29 | Jordan Loyal Holtzman | Agents and methods for increasing brain chaperonin levels |
JP2003342171A (en) * | 2002-05-23 | 2003-12-03 | Usv Ltd | Composition for administering dithranol |
EP1476121A1 (en) * | 2002-02-08 | 2004-11-17 | Merck & Co., Inc. | Topical ivermectin composition |
WO2007053760A2 (en) * | 2005-11-01 | 2007-05-10 | Dow Agrosciences Llc | Pesticidally active compositions having enhanced activity |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
KR101085157B1 (en) * | 2007-08-31 | 2011-11-18 | 한국화학연구원 | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same |
CN103070951A (en) * | 2013-02-01 | 2013-05-01 | 吉林农业大学 | Externally used medicinal composition for treating cattle mange and preparation method thereof |
EP2653160A1 (en) * | 2006-10-12 | 2013-10-23 | Topaz Pharmaceuticals Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of body lice |
US8765697B2 (en) | 2009-04-30 | 2014-07-01 | Dow Agrosciences, Llc. | Pesticide compositions exhibiting enhanced activity |
US8785379B2 (en) | 2009-04-30 | 2014-07-22 | Dow Agrosciences, Llc. | Pesticide compositions exhibiting enhanced activity |
US8796476B2 (en) | 2009-04-30 | 2014-08-05 | Dow Agrosciences, Llc | Pesticide compositions exhibiting enhanced activity and methods for preparing same |
WO2015073439A1 (en) * | 2013-11-12 | 2015-05-21 | Lipotec Laboratories Llc | Liposome-attractant formulations |
CN105338816A (en) * | 2014-06-05 | 2016-02-17 | 南斯泰克有限公司 | Method for preparing composition for environmentally friendly agricultural chemicals and fertilizers, using liquid sulfur |
US9445975B2 (en) | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
US20160278373A1 (en) * | 2004-06-01 | 2016-09-29 | Agscitech Inc. | Biosurfactant compositions and methods for providing plant nutrients |
EP2348832B1 (en) | 2008-10-29 | 2019-01-16 | Arbor Pharmaceuticals, LLC | Preservative system for emulsion-based therapeutic topical formulations |
CN110393187A (en) * | 2019-09-05 | 2019-11-01 | 湖南宇山玉月农业科技有限公司 | A kind of red turpentine beetle insecticide |
EP3794028A4 (en) * | 2018-05-15 | 2022-05-11 | Flagship Pioneering Innovations VI, LLC | Pathogen control compositions and uses thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1620113B1 (en) * | 2003-04-24 | 2011-07-13 | Galderma S.A. | Topical formulation of ivermectin for the treatment of dermatological conditions |
FR2867684B1 (en) * | 2004-03-18 | 2006-05-05 | Galderma Sa | CREAM GEL CONTAINING IVERMECTIN |
BR112020023032A2 (en) * | 2018-05-15 | 2021-02-09 | Flagship Pioneering Innovations Vi, Llc | pest control compositions and their uses |
AR116016A1 (en) * | 2018-08-24 | 2021-03-25 | Flagship Pioneering Innovations Vi Llc | METHODS FOR MANUFACTURING VEGETABLE MESSENGER PACKAGES |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173303A (en) * | 1989-05-25 | 1992-12-22 | Technology Unlimited, Inc. | Cutaneous delivery of organic materials |
US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4199569A (en) * | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
NZ197796A (en) * | 1980-08-04 | 1984-11-09 | Merck & Co Inc | Stabilised aqueous formulations containing ivermectin |
US5019392A (en) * | 1988-03-03 | 1991-05-28 | Micro-Pak, Inc. | Encapsulation of parasiticides |
FR2655542B1 (en) * | 1989-12-13 | 1994-02-11 | Oreal | COSMETIC COMPOSITION FOR TOPICAL APPLICATION CONTAINING ESSENTIAL OILS. |
RU2160093C2 (en) * | 1993-11-16 | 2000-12-10 | Скайефарма Инк. | Vesicles with controlled active ingredient release |
WO1995031970A1 (en) * | 1994-05-24 | 1995-11-30 | Agri-Tek, Inc. | Method of preparing a predetermined active agent stock solution for liposomal microencapsulation of active agents for agricultural uses |
FR2761912B1 (en) * | 1997-04-14 | 1999-07-02 | Capsulis | PROCESS FOR ADHERING A PRODUCT TO A SURFACE |
US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
ATE397488T1 (en) * | 1998-11-13 | 2008-06-15 | Heriot William A | DEVICE FOR PRODUCING LIPOSOMES |
-
2000
- 2000-01-24 WO PCT/US2000/001743 patent/WO2000042990A1/en active IP Right Grant
- 2000-01-24 AU AU26272/00A patent/AU781703B2/en not_active Ceased
- 2000-01-24 JP JP2000594447A patent/JP2002535268A/en active Pending
- 2000-01-24 EP EP00904531A patent/EP1154755A4/en not_active Withdrawn
- 2000-01-24 MX MXPA01007486A patent/MXPA01007486A/en not_active Application Discontinuation
- 2000-01-24 IL IL14456100A patent/IL144561A0/en active IP Right Grant
-
2001
- 2001-07-25 IL IL144561A patent/IL144561A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173303A (en) * | 1989-05-25 | 1992-12-22 | Technology Unlimited, Inc. | Cutaneous delivery of organic materials |
US5766627A (en) * | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
Non-Patent Citations (1)
Title |
---|
See also references of EP1154755A4 * |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001089500A3 (en) * | 2000-05-24 | 2002-04-25 | Jordan Loyal Holtzman | Agents and methods for increasing brain chaperonin levels |
WO2001089500A2 (en) * | 2000-05-24 | 2001-11-29 | Jordan Loyal Holtzman | Agents and methods for increasing brain chaperonin levels |
EP1476121A4 (en) * | 2002-02-08 | 2010-10-27 | Merck Sharp & Dohme | Topical ivermectin composition |
EP1476121A1 (en) * | 2002-02-08 | 2004-11-17 | Merck & Co., Inc. | Topical ivermectin composition |
JP2003342171A (en) * | 2002-05-23 | 2003-12-03 | Usv Ltd | Composition for administering dithranol |
US20160278373A1 (en) * | 2004-06-01 | 2016-09-29 | Agscitech Inc. | Biosurfactant compositions and methods for providing plant nutrients |
WO2007053760A2 (en) * | 2005-11-01 | 2007-05-10 | Dow Agrosciences Llc | Pesticidally active compositions having enhanced activity |
WO2007053760A3 (en) * | 2005-11-01 | 2008-01-10 | Dow Agrosciences Llc | Pesticidally active compositions having enhanced activity |
EP2374449A2 (en) * | 2006-04-19 | 2011-10-12 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
WO2007119028A3 (en) * | 2006-04-19 | 2008-04-03 | Galderma Sa | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
US9592249B2 (en) | 2006-04-19 | 2017-03-14 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
EP2374449A3 (en) * | 2006-04-19 | 2012-02-29 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
US8362069B2 (en) | 2006-04-19 | 2013-01-29 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
FR2900052A1 (en) * | 2006-04-19 | 2007-10-26 | Galderma Sa | COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN |
EP2653160A1 (en) * | 2006-10-12 | 2013-10-23 | Topaz Pharmaceuticals Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of body lice |
US11229207B2 (en) | 2006-10-12 | 2022-01-25 | Arbor Pharmaceuticals, Llc | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice |
US8791153B2 (en) | 2006-10-12 | 2014-07-29 | Sanofi-Topaz, Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice |
US8927595B2 (en) | 2006-10-12 | 2015-01-06 | Sanofi-Topaz, Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice |
KR101085157B1 (en) * | 2007-08-31 | 2011-11-18 | 한국화학연구원 | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same |
US9445975B2 (en) | 2008-10-03 | 2016-09-20 | Access Business Group International, Llc | Composition and method for preparing stable unilamellar liposomal suspension |
EP2348832B1 (en) | 2008-10-29 | 2019-01-16 | Arbor Pharmaceuticals, LLC | Preservative system for emulsion-based therapeutic topical formulations |
US8765697B2 (en) | 2009-04-30 | 2014-07-01 | Dow Agrosciences, Llc. | Pesticide compositions exhibiting enhanced activity |
US9374997B2 (en) | 2009-04-30 | 2016-06-28 | Dow Agrosciences Llc | Pesticide compositions exhibiting enhanced activity |
US9247730B2 (en) | 2009-04-30 | 2016-02-02 | Dow Agrosciences Llc | Pesticide compositions exhibiting enhanced activity and methods for preparing same |
US9480256B2 (en) | 2009-04-30 | 2016-11-01 | Dow Agrosciences Llc | Pesticide compositions exhibiting enhanced activity |
US8796476B2 (en) | 2009-04-30 | 2014-08-05 | Dow Agrosciences, Llc | Pesticide compositions exhibiting enhanced activity and methods for preparing same |
US8785379B2 (en) | 2009-04-30 | 2014-07-22 | Dow Agrosciences, Llc. | Pesticide compositions exhibiting enhanced activity |
CN103070951A (en) * | 2013-02-01 | 2013-05-01 | 吉林农业大学 | Externally used medicinal composition for treating cattle mange and preparation method thereof |
US20160270400A1 (en) * | 2013-11-12 | 2016-09-22 | Lipotec Laboratories Llc | Liposome-Attractant Formulations |
WO2015073439A1 (en) * | 2013-11-12 | 2015-05-21 | Lipotec Laboratories Llc | Liposome-attractant formulations |
CN105338816A (en) * | 2014-06-05 | 2016-02-17 | 南斯泰克有限公司 | Method for preparing composition for environmentally friendly agricultural chemicals and fertilizers, using liquid sulfur |
EP3794028A4 (en) * | 2018-05-15 | 2022-05-11 | Flagship Pioneering Innovations VI, LLC | Pathogen control compositions and uses thereof |
CN110393187A (en) * | 2019-09-05 | 2019-11-01 | 湖南宇山玉月农业科技有限公司 | A kind of red turpentine beetle insecticide |
Also Published As
Publication number | Publication date |
---|---|
IL144561A0 (en) | 2002-05-23 |
AU781703B2 (en) | 2005-06-09 |
JP2002535268A (en) | 2002-10-22 |
IL144561A (en) | 2007-07-04 |
MXPA01007486A (en) | 2003-06-24 |
AU2627200A (en) | 2000-08-07 |
EP1154755A4 (en) | 2003-08-13 |
EP1154755A1 (en) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU781703B2 (en) | Liposome formulations | |
KR960005137B1 (en) | Lipospheres for controlled delivery of substances | |
US5221535A (en) | Sustained release formulations of insect repellent | |
AU2008203312B2 (en) | Methods and compositions for treating ectoparasite infestation | |
US20220095621A1 (en) | Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice | |
IE904098A1 (en) | Lipospheres for controlled delivery of substances | |
JPH10500687A (en) | Antibacterial oil-in-water emulsion | |
US20030040504A1 (en) | Ectoparasiticidal compositions and methods of their use | |
US20160270400A1 (en) | Liposome-Attractant Formulations | |
WO2013192190A1 (en) | Liposome formulations | |
EA002756B1 (en) | Pesticidal composition in the form of water-soluble granules | |
CA2686336A1 (en) | Topical formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice with multiple modes of action |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AU CA CR DM GD HR IL IN JP MA MX TZ YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2000 594447 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/007486 Country of ref document: MX Ref document number: 144561 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000904531 Country of ref document: EP Ref document number: 26272/00 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2000904531 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 26272/00 Country of ref document: AU |